Randomized phase III study of nedaplatin (N) plus docetaxel (D) versus cisplatin (C) plus D for advanced or relapsed squamous cell carcinoma of the lung (SqLC): WJOG5208L.
Takehito Shukuya(Juntendo University), Nobuyuki Yamamoto(Wakayama Medical University), Toshiaki Takahashi(Okayama University), Kōichi Goto(National Cancer Center Hospital East), Tomoya Kawaguchi(Osaka Metropolitan University), Tetsuya Oguri(Miyoshi Kasei (Japan)), Takashi Nishimura(Hyogo University), Takashi Seto(National Hospital Organization Kyushu Cancer Center), Haruko Daga(Osaka City General Hospital), Shunichi Sugawara(Sendai Kousei Hospital), Hiroyasu Kaneda(Osaka City University), Kazuhiko Nakagawa(Osaka Red Cross Hospital), Yoshihiro Hattori(Hyogo Prefectural Cancer Center), Hideo Saka(Nagoya Medical Center), Yasuo Iwamoto(Hiroshima City Asa Citizens Hospital), Seisuke Nagase(Tokyo Medical University), Yoichi Nakanishi(RIKEN Center for Integrative Medical Sciences), Soichiro Yokota(Toneyama National Hospital), Takeharu Yamanaka(National Cancer Center Hospital East)
Cited by 4
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k